Log in

ASX:NC6Nanollose Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume516,254 shs
Average VolumeN/A
Market Capitalization$6.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre; and a commercial supply chain of microbial cellulose from various waste streams. Its products are used in textile, clothing, and other industries. Nanollose Limited has a collaborative research agreement with Umeå University, MoRe Research, and RISE Processum. The company was founded in 2014 and is based in Nedlands, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 9389 3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$697,693.00
Book ValueA$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$6.38 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NC6 News and Ratings via Email

Sign-up to receive the latest news and ratings for NC6 and its competitors with MarketBeat's FREE daily newsletter.

Nanollose (ASX:NC6) Frequently Asked Questions

Has Nanollose been receiving favorable news coverage?

Media stories about NC6 stock have trended negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nanollose earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Nanollose.

Who are some of Nanollose's key competitors?

Who are Nanollose's key executives?

Nanollose's management team includes the following people:
  • Dr. Wayne Morris Best, Exec. Chairman
  • Mr. Raffaele Germano, CEO, MD & Director
  • Mr. Gary Cass, Exec. Director of R&D and Exec. Director
  • Ms. Erlyn Saromines Dale A.C.I.S., B.Com., BCom., GradDipACG, AGIA, ACIS, Company Sec.

What is Nanollose's stock symbol?

Nanollose trades on the ASX under the ticker symbol "NC6."

How big of a company is Nanollose?

Nanollose has a market capitalization of $0.00 and generates $697,693.00 in revenue each year.

What is Nanollose's official website?

The official website for Nanollose is www.nanollose.com.

How can I contact Nanollose?

The company can be reached via phone at 61 8 9389 3120.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.